Sex differences in atherosclerosis in mice with elevated phospholipid transfer protein activity are related to decreased plasma high density lipoproteins and not to increased production of triglycerides

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1761, Issue 9, 2006, Pages 1070-1077

  Lie, Jessica ^a   Moerland, Matthijs ^a   van Gent, Teus ^a   van Haperen, Rien ^a   Scheek, Leo ^a   Sadeghi Niaraki, Farah ^a   de Crom, Rini ^a   van Tol, Arie ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Lipid metabolism; Lipoprotein; Transgenic animal model

Indexed keywords

CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PHOSPHOLIPID TRANSFER PROTEIN; TRIACYLGLYCEROL;

ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROGENIC DIET; ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOGENESIS; LIPOPROTEIN BLOOD LEVEL; LIVER; MALE; MOUSE; NONHUMAN; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE;

ANIMALS; AORTIC VALVE; ATHEROSCLEROSIS; CHOLESTEROL ESTER TRANSFER PROTEINS; DIET, ATHEROGENIC; FEMALE; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, VLDL; MALE; MICE; MICE, TRANSGENIC; PHOSPHOLIPID TRANSFER PROTEINS; RECEPTORS, LDL; SEX FACTORS; TRIGLYCERIDES;

ANIMALIA; MUS MUSCULUS;

EID: 33748446990     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2006.06.013     Document Type: Article

References (39)

1. Lusis A.J. Atherosclerosis. Nature 407 (2000) 233-241
2. Glass C.K., and Witztum J.L. Atherosclerosis. the road ahead. Cell 104 (2001) 503-516
3. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat. Med. 8 (2002) 1211-1217
4. Libby P. Managing the risk of atherosclerosis: the role of high-density lipoprotein. Am. J. Cardiol. 88 (2001) 3N-8N
5. Sviridov D., and Nestel P. Dynamics of reverse cholesterol transport: protection against atherosclerosis. Atherosclerosis 161 (2002) 245-254
6. Assmann G., and Nofer J.R. Atheroprotective effects of high-density lipoproteins. Annu. Rev. Med. 54 (2003) 321-341
7. Brewer Jr. H.B., and Santamarina-Fojo S. New insights into the role of the adenosine triphosphate-binding cassette transporters in high-density lipoprotein metabolism and reverse cholesterol transport. Am. J. Cardiol. 91 (2003) 3E-11E
8. Van Lenten B.J., Navab M., Shih D., Fogelman A.M., and Lusis A.J. The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc. Med. 11 (2001) 155-161
9. Nofer J.R., Kehrel B., Fobker M., Levkau B., Assmann G., and von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 161 (2002) 1-16
10. Barter P., Kastelein J., Nunn A., and Hobbs R. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 168 (2003) 195-211
11. van Tol A. Phospholipid transfer protein. Curr. Opin. Lipidol. 13 (2002) 135-139
12. van Haperen R., van Tol A., van Gent T., Scheek L., Visser P., van der Kamp A., Grosveld F., and de Crom R. Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J. Biol. Chem. 277 (2002) 48938-48943
13. Jiang X.C., Qin S., Qiao C., Kawano K., Lin M., Skold A., Xiao X., and Tall A.R. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat. Med. 7 (2001) 847-852
14. Lie J., De Crom R., Van Gent T., Van Haperen R., Scheek L., Lankhuizen I., and Van Tol A. Elevation of plasma phospholipid transfer protein in transgenic mice increases VLDL secretion. J. Lipid Res. 43 (2002) 1875-1880
15. van Ree J.H., van den Broek W.J., Dahlmans V.E., Groot P.H., Vidgeon-Hart M., Frants R.R., Wieringa B., Havekes L.M., and Hofker M.H. Diet-induced hypercholesterolemia and atherosclerosis in heterozygous apolipoprotein E-deficient mice. Atherosclerosis 111 (1994) 25-37
16. Arai T., Wang N., Bezouevski M., Welch C., and Tall A.R. Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. J. Biol. Chem. 274 (1999) 2366-2371
17. Daugherty A. Mouse models of atherosclerosis. Am. J. Med. Sci. 323 (2002) 3-10
18. Lie J., de Crom R., Jauhiainen M., van Gent T., van Haperen R., Scheek L., Jansen H., Ehnholm C., and van Tol A. Evaluation of phospholipid transfer protein and cholesteryl ester transfer protein as contributors to the generation of prebeta-high-density lipoproteins. Biochem. J. 360 (2001) 379-385
19. Barter P.J., Brewer Jr. H.B., Chapman M.J., Hennekens C.H., Rader D.J., and Tall A.R. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 160-167
20. Parini P., and Rudel L.L. Is there a need for cholesteryl ester transfer protein inhibition?. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 374-375
21. van Haperen R., van Tol A., Vermeulen P., Jauhiainen M., van Gent T., van den Berg P., Ehnholm S., Grosveld F., van der Kamp A., and de Crom R. Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 1082-1088
22. Van Haperen R., De Waard M., Van Deel E., Mees B., Kutryk M., Van Aken T., Hamming J., Grosveld F., Duncker D.J., and De Crom R. Reduction of blood pressure, plasma cholesterol and atherosclerosis by elevated endothelial nitric oxide. J. Biol. Chem. 277 (2002) 48803-48807
23. Delsing D.J., Offerman E.H., van Duyvenvoorde W., van Der Boom H., de Wit E.C., Gijbels M.J., van Der Laarse A., Jukema J.W., Havekes L.M., and Princen H.M. Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice. Circulation 103 (2001) 1778-1786
24. Lie J., de Crom R., van Gent T., van Haperen R., Scheek L., Sadeghi-Niaraki F., and van Tol A. Elevation of plasma phospholipid transfer protein increases the risk of atherosclerosis despite lower apolipoprotein B-containing lipoproteins. J. Lipid Res. 45 (2004) 805-811
25. Warden C.H., Hedrick C.C., Qiao J.H., Castellani L.W., and Lusis A.J. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science 261 (1993) 469-472
26. Callow M.J., Verstuyft J., Tangirala R., Palinski W., and Rubin E.M. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a). J. Clin. Invest. 96 (1995) 1639-1646
27. Purcell-Huynh D.A., Farese Jr. R.V., Johnson D.F., Flynn L.M., Pierotti V., Newland D.L., Linton M.F., Sanan D.A., and Young S.G. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J. Clin. Invest. 95 (1995) 2246-2257
28. Hughes S.D., Verstuyft J., and Rubin E.M. HDL deficiency in genetically engineered mice requires elevated LDL to accelerate atherogenesis. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 1725-1729
29. de Winther M.P., Gijbels M.J., van Dijk K.W., van Gorp P.J., suzuki H., Kodama T., Frants R.R., Havekes L.M., and Hofker M.H. Scavenger receptor deficiency leads to more complex atherosclerotic lesions in APOE3Leiden transgenic mice. Atherosclerosis 144 (1999) 315-321
30. Dansky H.M., Charlton S.A., Sikes J.L., Heath S.C., Simantov R., Levin L.F., Shu P., Moore K.J., Breslow J.L., and Smith J.D. Genetic background determines the extent of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 1960-1968
31. Zhang S.H., Reddick R.L., Burkey B., and Maeda N. Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption. J. Clin. Invest. 94 (1994) 937-945
32. O'Brien K.D., Vuletic S., McDonald T.O., Wolfbauer G., Lewis K., Tu A.Y., Marcovina S., Wight T.N., Chait A., and Albers J.J. Cell-associated and extracellular phospholipid transfer protein in human coronary atherosclerosis. Circulation (2003) 270-274
33. Laffitte B.A., Joseph S.B., Chen M., Castrillo A., Repa J., Wilpitz D., Mangelsdorf D., and Tontonoz P. The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. Mol. Cell. Biol. 23 (2003) 2182-2191
34. Fazio S., and Linton M.F. Mouse models of hyperlipidemia and atherosclerosis. Front. Biosci. 6 (2001) D515-D525
35. Plump A.S., Masucci-Magoulas L., Bruce C., Bisgaier C.L., Breslow J.L., and Tall A.R. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 1105-1110
36. Masucci-Magoulas L., Plump A., Jiang X.C., Walsh A., Breslow J.L., and Tall A.R. Profound induction of hepatic cholesteryl ester transfer protein transgene expression in apolipoprotein E and low density lipoprotein receptor gene knockout mice. A novel mechanism signals changes in plasma cholesterol levels. J. Clin. Invest. 97 (1996) 154-161
37. Marotti K.R., Castle C.K., Boyle T.P., Lin A.H., Murray R.W., and Melchior G.W. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 364 (1993) 73-75
38. Herrera V.L., Makrides S.C., Xie H.X., Adari H., Krauss R.M., Ryan U.S., and Ruiz-Opazo N. Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein. Nat. Med. 5 (1999) 1383-1389
39. Okamoto H., Yonemori F., Wakitani K., Minowa T., Maeda K., and Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406 (2000) 203-207